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82 Poster Session Ibetween the two groups with respect to age, gender, disease type, or
CMVstatus. Likewise, therewere no significant differences between
thePCTand control groupswith respect to donor source (related vs.
unrelated), progenitor cell source (BM vs. UCB) or HLA disparity.
In this cohort, PCT patients were more likely to have grade II-IV
aGVHD (86 vs. 35%, p 5 0.01) and grade III-IV aGVHD (35 vs.
15%, p 5 0.03). Similarly, PCT patients were more likely to have
cGVHD (36% vs. 13%, p 5 0.01). The cumulative incidence of
non-relapsemortality and overall survival at 5 yrs, however,was sim-
ilar in both groups (p5 0.29 and p5 0.12, respectively). In univar-
iate analysis, a significantly lower risk of relapse at 3 years was noted
in patients with PCT (0% vs. 30% [25–36%], p5 0.02). In Cox re-
gression, aGVHD (p5 0.05), cGVHD (p5 0.01) and development
of PCT (p\0.01) were associated with protection form relapse. Of
the 6 deaths in the PCT group, 5 patients had pulmonary complica-
tions at the time of death. Collectively these data suggest that pa-
tients with PCT are at high risk for cGVHD and pulmonary
associated toxicity, but lower risk of relapse.
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HYPERCALCEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR OSTEOPETROSIS
Martinez, C.1, Orchard, P.J.1, Wagner, J.E.1, Petryk, A.2, Tolar, J.1.
1University of Minnesota, Minneapolis, MN; 2University of Minnesota,
Minneapolis, MN.
Osteopetrosis (OP) is a clinical syndrome characterized by insuf-
ficient osteoclastic activity resulting in defective bone resorption
and marked increase in bone density. The recessive form of osteo-
petrosis (‘‘malignant osteopetrosis’’) has been successfully treated
with allogeneic hematopoietic cell transplantation (HCT), second-
ary to engraftment of donor-derived functioning osteoclasts result-
ing in bony remodeling and establishment of normal hematopoiesis.
While hypocalcemia is a common presenting feature of recessive os-
teopetrosis, hypercalcemia may be observed following HCT due to
rapid engraftment of osteoclasts differentiated from the hematopoi-
etic precursors. To investigate the incidence of hypercalcemia after
HCT, we have evaluated nine patients with osteopetrosis (a median
age of 2 years, range 0.5 – 28 yrs) treated at the University of Min-
nesota during a 7 year period (2000–2007). Eight patients were re-
ceiving their initial transplant, and one patient received a second
HCT, following graft failure. The conditioning regimen consisted
of busulfan, fludarabine, equine ATG and total lymphoid irradia-
tion. Donor grafts consisted of URD BM (2), URD UCB (3),
REL PBSC (2), and URD PBSC (2). All patients that received
a BM or PBSC graft engrafted with donor grafts, while recipients
of UCB had a transient partial engraftment followed by autologous
recovery. The median day of myeloid recovery (defined as an abso-
lute neutrophil count of 500 or above for 3 consecutive days) was
day 20 (range 14–42 days). Elevated calcium levels were found in
three of the nine patients. The elevation of calcium levels was ob-
served at a median day 12 (range 10–15) which correlated with ini-
tial count recovery. The median day of highest calcium levels in
these three patients was day 21 with a mean calcium level of 12.9
mg/dL (SD 1.18). Clinically, hypercalcemia was managed with in-
travenous fluids, furosemide diuresis and calcitonin. The median
age of the group of patients with hypercalcemia was 24 years. In
contrast the median age of the patients that didn’t experience hyper-
calcemia was 1 year of age. No correlation was found between hy-
percalcemia and type of donor graft, HLA match, or CD341 cell
dose. The implications of the current study are that hypercalcemia
occurs after HCT in approximately one third of theOP patients and
that it may be more common in older patients, perhaps due to age
dependent increase in bone mass.
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TOLERABILITY OF DAPSONE IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT
O’Connor, M.R., Duncan, C., Myers, K., Lehmann, L. Dana-Farber
Cancer Institue, Boston, MA.
Dapsone is a commonly used drug for pneumocystis carinii pneu-
monia (PCP) prophylaxis in pediatric Hematopoietic Stem CellTransplant (HSCT) patients. However, its use is frequently limited
by toxicities such as hemolysis and methemoglobinemia. We per-
formed a retrospective medical record review of all pediatric
HSCT patients at our institution between January 1, 2001 and
June 8, 2007. We identified all patients that received dapsone as
PCP prophylaxis and documented course limiting adverse effects.
402 patients received 447 transplants during the study period. Dap-
sone was prescribed as PCP prophylaxis in 111 instances (24.8%). In
27.9% of these instances patients completed the recommended
course without incident. 72.1% of the time patients were changed
to an alternative prophylactic agent due to dapsone-associated ad-
verse events.Hemolysis was themost common reason for discontin-
uation of dapsone and it occurred in 41(36.9%) cases.
Methemoglobinemia was the second most common adverse effect
and it occurred in 27 (24.3%) instances. The mean methemoglobin
level for this group was 4.4% with a range of 2.2–16% (upper limit
of normal at our institution is 1.5%). Dapsone was discontinued in
the remaining patients because of rash (7), increased liver function
tests (1), and tachycardia and vertigo (1). Three patients were lost
to follow-up. In patients who received dapsone there were no docu-
mented cases of PCP.Dapsonewas an effective, yet poorly tolerated
agent in this group of pediatric stem cell transplant patients. Pro-
viders should maintain a high level of awareness for toxicities
when utilizing dapsone in pediatric stem cell transplant patients.221
PRELIMINARY RESULTS OF NON-ABLATIVE CONDITIONING (NAC)
WITH BUSULFAN (Bu), FLUDARABINE (Flu) AND ALEMTUZUMAB FOL-
LOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) TO
INDUCE MIXED DONOR CHIMERISM IN PATIENTS WITH SICKLE CELL
DISEASE (SCD)
Bhatia, M.1, Baldinger, L.1, Billote, G.1, Morris, E.1, Bradley, M.B.1,
George, D.1, Garvin, J.1, Satwani, P.1, Schwartz, J.1, Wolownik, K.1,
Foley, S.1, Hawks, R.1, Baxter-Lowe, L.A.2, Cairo, M.S.1. 1Columbia
University, New York, NY; 2UCSF, San Francisco, CA.
SCD is associated with a decrease in lifespan and quality of life in
children. The only known cure is AlloSCT from a matched family
donor with only 15% of patients having an unaffected, HLA-
matched identical sibling. Patients undergoing myeloablative Al-
loSCT are at risk for numerous complications post SCT including
death, graft versus host disease (GVHD), and infections. Full donor
chimerism is not necessary to correct the underlying genetic defect
and eliminate symptoms in patients with SCD. In this study, we re-
port the preliminary results of NAC and AlloSCT from related
matched family and unrelated umbilical cord blood (UCB) donors
in 7 patients (7M:0F) with high risk SCD (HbSS 5 4, HbSC 5 2,
HbSßThal 5 1). Conditioning was Bu (4 mg/kg  4 d # 4 yrs
and 12.8 mg/kg  4 d . 4 yrs), Flu (30 mg/m2  6 d), and Alemtu-
zumab (2 mg/m2 1 d, 6 mg/m2 2 d, and 25 mg/m2 2 d). UCB
recipients also received rabbit antithymocyte globulin (2 mg/kg 4
d). Mean age was 5.8 years 1/-4.03 (1.4–13.75 years). Donor sour-
ces were: 2 6/6 HLA-matched sibling bone marrow (BM), 2 6/6
HLA-matched UCB, and 3 4/6 unrelated UCB. Mean cell dose
was 12.021/-13.0  107 TNC/kg and 1.031/-1.66  106 CD34/
kg. Patients received tacrolimus and mycophenolate mofetil as
GVHD prophylaxis and phenytoin as seizure prophylaxis for 180
days post SCT. Of 5 patients evaluable for myeloid recovery (1
did not nadir, 1 too early), mean neutrophil and platelet recovery
was on day1306 7(n5 5) and day1606 18(n5 5), respectively.
One patient had primary graft failure at day 160 post SCT (Bu
steady state concentration (Css) 552 ng/ml). Busulfan pharmakoki-
netics were then changed to maintain Css between 600–900 ng/ml.
Mean whole blood donor chimerism on days 130, 160, and 1100
was 49%633(n5 6), 61%632(n5 5), and 82%613(n5 4), respec-
tively. More recently, erythroid engraftment (CD71) is being deter-
mined. Mean CD71 chimerism on days 130 and 160 was
55.3%641(n 5 3) and 61.1%617.5(n 5 3), respectively. Hb elec-
trophoresis was done on all patients with mean %HbS levels of
1.80 6 1.02(n 5 5) and 7.46 6 9.88(n 5 5) on days 130 and
1100, respectively. Grades II-IV acute GVHD was seen in 3/7 pa-
tients(42%). Chronic extensive GVHD was seen in 1/5(20%) pa-
tients. All patients are alive with the longest follow up being 1120
